Cancer Drug Discovery, Softcover reprint of the original 1st ed. 2016 Science and History

The reader will discover a comprehensive and multifaceted overview of the history of the development of anticancer drugs deeply influenced by the cell concept of cancer and future directions for the development of new anticancer drugs. First, this book documents the scientific progress in biological science over the last 70 years and the influence this progress had in cancer research. Summaries and charts of important discoveries complete this overview. Furthermore, this book outlines the process of anticancer drug development with a focus on the characteristic drug groups of each era, related to advancements of chemistry and biological sciences. This book also provides brief mechanism of action of drugs, illustrated by comprehensive timelines and conceptual cartoons. This book finally sums up the limitations of the current anticancer drug development and seeks new directions for anticancer drug discovery, considering under the systemic view of cancer.

Part Ⅰ. A Scientific Overview on Cancer.- 1. Advancements in Life Sciences and Characteristic Features of Cancer Cells.- 1.1 Characteristics of cancer cells.- 1.2 Characteristic interactions of cancer cells with neighboring cells and the tumor microenvironment.- 2. Advancement of the Science and History of Cancer and Anticancer Drugs.- Part Ⅱ. Cancer Drug Discovery – Types and History.- 3. Chronology of Anticancer Drug Development.- 3.1 A historical background of cancer chemotherapy.- 3.2 Development of the anticancer drug screening systems.- 3.3 Chronology of the anticancer drug development.- 3.4 Clinical application of anticancer drugs.- 4. Alkylating Anticancer Drugs.- 4.1 Classical alkylating drugs.- 4.2 Nonclassical alkylating drugs.- 4.3 Alkylating-like agents: platinum compounds.- 5. Antimetabolic Anticancer Drugs.- 5.1 Folic acid derivatives.- 5.2 Purine analogs.- 5.3 Pyrimidine analogs.- 6. Natural Product Anticancer Drugs.- 6.1 Plant-derived anticancer drugs.- 6.2 Anticancer antibiotics.- 7. Immunotherapeutic Anticancer Drugs and Other Miscellaneous Anticancer Drugs.- 7.1 Immunotherapeutic anticancer drugs.- 7.2 Other miscellaneous anticancer drugs.- 8. Hormonal Anticancer Drugs.- 8.1 Hormonal anti-prostate-cancer drugs.- 8.2 Hormonal anti-breast-cancer drugs.- 8.3 Other hormonal anticancer drugs.- 9. Molecular Targeted Anticancer Drugs.- 9.1 Tretinoin (all-trans retinoic acid, ATRA).- 9.2 Bcr-Abl Inhibitors.- 9.3 EGFR inhibitors.- 9.4 HER2 inhibitors.- 9.5 Angiogenesis inhibitors.- 9.6 Other kinase inhibitors.- 9.7 mTOR inhibitors.- 9.8 Other targeted anticancer antibody drugs.- 9.9 Epigenetic anticancer drugs.- 9.10 Proteasome inhibitors.- 9.11 Vismodegib: hedgehog pathway blocker.- 10. Complications of Anticancer Drugs and Their Management.- 10.1 Chemotherapy-induced nausea and vomiting (CINV).- 10.2 Myelotoxicity (bone marrow toxicity).- 10.3 Chemotherapy-induced diarrhea.- 10.4 Chemotherapy-induced constipation.- 10.5 Chemotherapy-induced urinary toxicity.- 10.6 Chemotherapy-induced pulmonary toxicity.- 10.7 Chemotherapy-induced neurotoxicity.- 10.8 Chemotherapy-induced neurotoxicity.- 10.9 Chemotherapy-induced oral mucositis.- 10.10 Anorexia.- 10.11 Tumor lysis syndrome.- 10.12 Extravasation of anticancer drugs.- 10.13 Chemotherapy-induced skin toxicity.- Part Ⅲ. A Paradigm Shift in Cancer Research.- 11. Advancements in Bioscience and New Cancer Drugs.- 11.1. Development of cancer drugs according to scientific advancements.- 11.2. New anticancer drugs.

Dr. Kyu-Won Kim College of Pharmacy, Seoul National University, Seoul, South Korea
Dr. Jae Kyung Roh Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea